Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504750 | 1.00 | DPP4 (0.55) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3505724 | 0.84 | DPP4 (0.64) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3505719 | 0.84 | DPP4 (0.64) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL4657207 | 0.81 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3504330 | 0.81 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3507073 | 0.81 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3504324 | 0.81 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL590923 | 0.80 | CA1 (0.62) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL28045116 | 0.80 | CA1 (0.62) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3507642 | 0.79 | DPP4 (0.57) | DPP4DPP7CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210635-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | claimed |
| EP-1999117-A2 | RENIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-12-10 | — | — | EP | claimed |
| WO-2007117961-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | WO | claimed |
| US-20100210635-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-1999117-A2 | RENIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007117961-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210635-A1 | RENIN INHIBITORS | REN, ACE, AGT | DPP4 25/4885DPP7 34/4885CA1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.